A PHASE I, MULTICENTER, RANDOMIZED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF VACCINIA-DERIVED MN HIV-1 RECOMBINANT ENVELOPE GLYCOPROTEIN (RGP160) OF HUMAN IMMUNODEFICIENCY VIRUS AT TWO DIFFERENT VACCINATION SCHEDULES: